Zitat:"TORONTO, April 07, 2020 (GLOBE NEWSWIRE) --QuestCap Inc. (“QuestCap” or the “Company”) (CSE: QSC; FRA: 34C1) announced today that it has entered into a profit sharing agreement with More Than Just Rice, Inc. (“MTJR”), subject to the satisfaction of conditions with a Korean diagnostic testing company, for MTJR to exclusively distribute, market and sell COVID19 Antibody Tests in North and South America. The test will be marketed/distributed in the United States pursuant to the U.S. Food and Drug Administration (FDA)’s policy on COVID-19 serological tests during the public health emergency period.COVID-19 Antibody Test Disclaimers:.......... test has not been reviewed by the FD.........negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals.............Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.........Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E..........
........Not for the screening of donated blood.The transaction will be structured as a profit-sharing agreement (the “Profit Sharing Agreement”) between QuestCap and MTJR. QuestCap has agreed to help finance the purchase of Antibody Tests for distribution in the Americas, and QuestCap will receive 40 per cent of any profits earned from the sale of the tests. QuestCap will also issue 10 million common shares to MTJR as consideration for entering the profit-sharing agreement at an effective price of $0.50 per common share, 5 million of which will be issued immediately on closing and the remaining 5 million common shares to be issued based on the achievement of performance targets.... " Ziat ENDE
Source/s:https://www.sedar.com/...nyDocuments.do?lang=EN&issuerNo=00024436
https://www.sedar.com/...=03&projectNo=03041916&docId=4698225
https://www.sedar.com/...=03&projectNo=03042041&docId=4698456 |
